Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,359 result(s) found. Displaying page 1,786 of 2,218.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    EudraCT Number: 2018-001744-62 Sponsor Protocol Number: 2018/2727 Start Date*: 2018-11-28
    Sponsor Name:Gustave Roussy
    Full Title: A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repai...
    Medical condition: •Molecularly selected cohorts that harbor DNA repair deficiency: –Non-Small Cell Lung Cancer –Urothelial Bladder Cancer –Metastatic Castration Resistant Prostate Cancer –Others: any histology, exce...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066350 Adenocarcinoma of the gastrooesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002889-41 Sponsor Protocol Number: UC-BCG-2103 Start Date*: 2022-04-29
    Sponsor Name:UNICANCER
    Full Title: LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in women with HR+ HER2- breast cancer at very low risk of metastasis
    Medical condition: Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083237 Luminal A breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001062-28 Sponsor Protocol Number: AC-055-312 Start Date*: 2017-01-25
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A multicenter, open-label, randomized, event-driven study to assess efficacy, safety and pharmacokinetics of macitentan versus standard of care in children with pulmonary arterial hypertension
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) AT (Completed) PT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Completed) FI (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2013-001870-38 Sponsor Protocol Number: GTi1201 Start Date*: 2014-01-09
    Sponsor Name:Grifols Therapeutics Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alphal-Proteinase Inhibitor (Human) in Sub...
    Medical condition: Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10014563 Emphysema pulmonary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IE (Completed) EE (Completed) DK (Trial now transitioned) ES (Completed) FI (Trial now transitioned) PL (Trial now transitioned) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001908-38 Sponsor Protocol Number: R5093-ONC-1863 Start Date*: 2020-09-28
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002845-39 Sponsor Protocol Number: Infmed1 Start Date*: 2019-10-02
    Sponsor Name:Aalborg University Hospital
    Full Title: Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL)
    Medical condition: Brain abscess
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10006105 Brain abscess PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004393-62 Sponsor Protocol Number: NBI-921352-DEE2013 Start Date*: 2022-03-18
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with SCN8A Developmental and Epileptic Encep...
    Medical condition: SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8ADEE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) FR (Ongoing) IT (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000259-35 Sponsor Protocol Number: 2020_03 Start Date*: 2022-04-29
    Sponsor Name:Centre Hospitalier Universitaire de Lille
    Full Title: Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections
    Medical condition: Overactive bladder (OAB) and/or detrusor overactivity (DO) in multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001887-31 Sponsor Protocol Number: RD.06.SPR.118161 Start Date*: 2020-02-19
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GB (GB - no longer in EU/EEA) DE (Completed) LT (Completed) NL (Completed) AT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003525-30 Sponsor Protocol Number: COLCAD Start Date*: 2022-01-06
    Sponsor Name:Aarhus University Hospital, Steno Diabetes Center Aarhus
    Full Title: Effect of colchicine on cardiovascular target organ damage in patients with type 2 diabetes - A randomized placebo-controlled trial
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000470-36 Sponsor Protocol Number: SEP361-301 Start Date*: Information not available in EudraCT
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001064 Acute schizophrenia LLT
    20.0 100000004873 10008525 Childhood schizophrenia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001501-69 Sponsor Protocol Number: NN9535-4820 Start Date*: 2022-07-26
    Sponsor Name:Novo Nordisk A/S
    Full Title: Investigation of Clinical Comparability of Semaglutide Drug Products Based on the Proposed and the Approved Drug Substance Manufacturing Processes in Participants with Type 2 Diabetes
    Medical condition: Diabetes mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004750-28 Sponsor Protocol Number: PropoCon-Pilot Start Date*: 2021-04-30
    Sponsor Name:Universitair Ziekenhuis Brussel
    Full Title: Electrocardiographic And Clinical Effects Of Target-Controlled Infusion Of Propofol In Adults With Brugada Syndrome. A Pilot Study.
    Medical condition: Target Controlled Infusion of Propofol in patients with Brugada Syndrome.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006639-24 Sponsor Protocol Number: 2020/ABM/01/00080 Start Date*: 2022-10-19
    Sponsor Name:The Cardinal Stefan Wyszyński Institute of Cardiology
    Full Title: Multicenter Polish Study of the Use of Bromocriptine in Perinatal Cardiomyopathy. New BioMarkers in the Early Diagnosis of Peripartum CardioMyopathy. PolBrom-PPCM
    Medical condition: PeriPartum Cardiomiopathy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004266-18 Sponsor Protocol Number: LTF-307 Start Date*: 2020-09-03
    Sponsor Name:bluebird bio, Inc.
    Full Title: Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
    Medical condition: Subjects with sickle-cell disease treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety an...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10040648 Sickle cell SC disease LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000365-41 Sponsor Protocol Number: CNTO1959UCO3004 Start Date*: 2023-04-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Mode...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001639-10 Sponsor Protocol Number: 787-201 Start Date*: 2023-06-09
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subje...
    Medical condition: Severe Alcohol-Associated Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006904-34 Sponsor Protocol Number: CHD21_0121 Start Date*: 2022-06-23
    Sponsor Name:Centre Hospitalier Départemental Vendée
    Full Title: Evaluation of the interest of perianal infiltration during thermodestruction of haemorrhoidal disease by Radiofrequency (RAFAELO® procedure)
    Medical condition: Hemorrhoidal surgery by thermodestruction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002363-26 Sponsor Protocol Number: NeoCol Start Date*: 2013-07-23
    Sponsor Name:Vejle Hospital
    Full Title: Neoadjuvant chemotherapy versus standard treatment in patients with locally advanced colon cancer
    Medical condition: Colon cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009951 Colon cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) SE (Ongoing) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004651-23 Sponsor Protocol Number: IJB-SYNERGY-012017 Start Date*: 2018-10-16
    Sponsor Name:Institut Jules Bordet
    Full Title: A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative ...
    Medical condition: Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Sep 20 15:35:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA